Did you know? You can suggest edits to improve this peptide information.
Overview
What is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from hCAP18 that exhibits broad-spectrum antimicrobial activity against bacteria, viruses, and fungi while modulating immune responses and promoting wound healing.
Key Benefits
Direct wound healing acceleration, local antimicrobial protection, enhanced tissue regeneration
Mechanism of Action
Topical application provides direct access to wound sites, promoting keratinocyte migration, angiogenesis, and antimicrobial protection without systemic exposure
Pharmacokinetics
Research Indications
Chronic Venous Leg Ulcers
Clinical trials show 68% ulcer area reduction with 0.5 mg/mL concentration
Diabetic Foot Ulcers
Enhanced granulation tissue formation and healing rate in clinical studies
Pressure Ulcers
Chitosan hydrogel delivery systems demonstrate accelerated healing in animal models
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Ensure wound area is properly cleaned and debrided if necessary
Apply thin layer of LL-37 gel or cream directly to wound surface
Cover with appropriate sterile dressing if recommended
Change dressing according to clinical protocol (typically daily to twice weekly)
Monitor wound healing progress and adjust application frequency as needed
Document wound measurements and healing progression
Quality Indicators
Sterile formulation
Topical LL-37 should be sterile with preservatives appropriate for wound care
Appropriate gel base
Compatible gel or cream base that doesn't interfere with peptide activity
Proper concentration
Clinical-grade concentrations (0.5-1.6 mg/mL) with verified potency
Cold storage maintenance
Maintained at 2-8°C throughout storage and transport
Contaminated products
Any signs of microbial contamination or non-sterile preparation
Improper pH formulation
pH outside physiological range that could irritate wound tissue
Homemade formulations
DIY topical preparations may lack sterility and proper formulation
What to Expect
- Week 1-2: Reduced bacterial load, initial wound bed preparation
- Week 2-4: Increased granulation tissue formation, epithelial migration
- Week 4-6: Significant wound size reduction, improved healing quality
- Week 6-8: Continued healing progress toward complete wound closure
Side Effects & Safety
- Use only on clean, debrided wounds as directed by healthcare provider
- Monitor for signs of wound infection or delayed healing
- Discontinue if signs of hypersensitivity or allergic reactions develop
- Use sterile technique for application to prevent contamination
References
MRSA Biofilm Eradication Study (2019)
CDC biofilm reactor study showing LL-37 achieved superior antimicrobial efficacy against Staphylococcus aureus biofilms compared to conventional antibiotics and silver nanoparticles.
View Study (opens in new tab) →Multidrug-Resistant Bacteria Study (2017)
Comprehensive antimicrobial profile study against human pathogens including antibiotic-resistant strains, demonstrating broad-spectrum activity and potential as alternative to conventional antibiotics.
View Study (opens in new tab) →Venous Leg Ulcer Clinical Trial (2014)
First-in-man randomized, placebo-controlled trial in 34 participants with hard-to-heal venous leg ulcers. Demonstrated significant wound healing improvement with 6-fold higher healing rate constants for optimal doses.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia